Biggest News Aggregation in the World
📰 Allogeneic News

Page 6 - Allogeneic News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Allogeneic. Real-time updates on events, politics, business and more.

Cellenkos Receives FDA Clearance of Investigational New Drug (IND) Application for CK0803 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

-- CK0803 are neurotropic, allogeneic, umbilical cord blood derived T regulatory (Treg) cells -- CK0803 represents the company's fifth program to receive IND Clearance utilizing Cellenkos' proprietary CRANEtechnology HOUSTON, Sept. 22, 2022 /PRNewswire/ -- Cellenkos, Inc., a clinical stage biotech company that focuses on developing transformative cellular therapeutics for treatment of inflammatory disorders and autoimmune diseases, today announced that the U.S. Food and Drug Administrati...
United States Tara Sadeghi Neil Shneider Cellenkos Inc Prnewswire Cellenkos Inc Center At Columbia University

Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates

First demonstration of the survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent non-human primate model without any immune... | June 17, 2022
San Francisco United States United Kingdom South San Francisco Sonja Schrepfer Steve Harr

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Ncardia Launches Cellistic, the Only iPSC-based Cell Therapy Process Development & Manufacturing Partner Purpose-built to Make Large-scale Allogeneic Cell Therapy Production a Reality Today

Ncardia has launched a new business, Cellistic, to focus Ncardia's induced pluripotent stem cell (iPSC) expertise on the cell therapy development and manufacturing sector. This strategy expands on Ncardia's
Andy Holt Kostenloser Wertpapierhandel Stefan Braam Elena Matsa Keith Hayes Cell Technology

Caribou Biosciences Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 at the American Association for Cancer Research (AACR) Annual Meeting

-- CB-011 is an allogeneic anti-BCMA CAR-T cell therapy immune cloaked to blunt both T- and NK-mediated immune cell rejection, enabling more durable antitumor activity -- -- Data support an... | April 8, 2022
United States Sylvia Wheeler Rachel Haurwitz Samy Figueroa Greg Kelley Steve Kanner

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science